To evaluate the role of flow cytometry crossmatching on graft survival in patients undergoing cadaveric renal retransplantation compared with our conventional antihuman globulin cytotoxic crossmatch.
In 1990, 6 of 7 transplantation centers in 1 organ procurement organization service area began performing cadaveric renal retransplantation only if the flow T-cell IgG crossmatch was negative. During that period, 1 center continued to use only the antihuman globulin T-cell IgG crossmatch. Prior to 1990, all centers used only the antihuman globulin T-cell IgG crossmatch as their crossmatch selection criterion for retransplantation. Regraft survival was compared between those centers by crossmatch selection criteria.
Patient selection and immunosuppression decisions were made at the transplantation center.
All flow cytometry crossmatches for all 7 centers participating in the evaluation were performed at the Histocompatibility Laboratory of the Midwest Organ Bank Inc, Westwood, Kan.
Graft survival is significantly better (P=.03 [logrank test]) in regrafts when the flow crossmatch is used to select patients for transplantation.
Flow crossmatching improves graft survival in cadaveric renal retransplantation by identifying a subset of patients with donor-directed HLA class I antibodies that are not detectable by our conventional antihuman globulin crossmatch.(Arch Surg. 1996;131:599-603)
Nelson PW, Eschliman P, Shield CF, et al. Improved Graft Survival in Cadaveric Renal Retransplantation by Flow Crossmatching. Arch Surg. 1996;131(6):599–603. doi:10.1001/archsurg.1996.01430180025004
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: